Clinical Trials Logo

Clinical Trial Summary

OBJECTIVES: I. Evaluate the tolerance of patients with blastomycosis, histoplasmosis, and sporotrichosis to different doses of itraconazole (R51,211).

II. Determine levels of itraconazole in serum and other body fluids. III. Assess the course of illness during itraconazole therapy. IV. Determine the dosage of itraconazole that is safe and well tolerated by 80%-90% of patients and estimate the potential of this dosage for use in future comparative trials.


Clinical Trial Description

PROTOCOL OUTLINE: This is a study to estimate the optimal dose of oral itraconazole. Patients are treated at 1 of 3 doses of itraconazole; the starting dose for each patient is determined at entry.

Therapy is administered daily for 3-6 months. Patients with progressive disease may be treated at the next higher dose; there may be only 1 such increase. Concurrent systemic and topical antifungals are prohibited.

Patients are followed at 1, 3, 6, and 12 months. ;


Study Design

Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00004811
Study type Interventional
Source Office of Rare Diseases (ORD)
Contact
Status Completed
Phase Phase 1/Phase 2
Start date March 1985

See also
  Status Clinical Trial Phase
Completed NCT00004808 - Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis Phase 2
Withdrawn NCT02911740 - Additive Benefit of the Urine LAM Test to Current TB Diagnostics in HIV Positive Adults in Panama City, Panama N/A
Completed NCT02493738 - A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers Phase 1
Completed NCT00784368 - A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection Phase 3
Completed NCT00000150 - Submacular Surgery Trials (SST) Phase 3
Active, not recruiting NCT00000158 - Macular Photocoagulation Study (MPS) Phase 3
Completed NCT04059770 - Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS Patients Phase 2
Completed NCT03059992 - Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Phase 3
Completed NCT00000627 - Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome N/A
Completed NCT00006316 - Withdrawal of Antifungal Treatment for Histoplasmosis in Patients After Improved Immune Response to Anti-HIV Drugs N/A
Completed NCT00000992 - A Study of Itraconazole in Preventing the Return of Histoplasmosis, a Fungal Infection, in Patients With AIDS Phase 1
Completed NCT00000975 - A Study of Itraconazole in the Treatment and Prevention of Histoplasmosis, a Fungal Infection, in Patients With AIDS Phase 2
Completed NCT00002159 - A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis Phase 3
Completed NCT00002438 - A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients N/A